Trial
NCT03737994
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
NRG Oncology
Condition
Lung Non-Squamous Non-Small Cell Carcinoma
Intervention
Alectinib
Why stopped
Inadequate accrual rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-23